Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|November 30, 2021

Building Biotech Series with Sue Fletcher

When university and industry researchers work in tandem to conquer big challenges in medicine, they can achieve much more together than they ever could apart. Sue Fletcher, a pioneer in RNA therapeutic and Chief Scientific Officer at PYC Therapeutics, know this firsthand. She has spent decades in the field and is the co-developer of some revolutionary genetic therapies for treating rare diseases. Here, Dr. Fletcher speaks with BioPharm International about her work in this field, her incredible career, and how she’s inspiring young scientists in this complex area.


Related to this article

The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.
Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.